DI
SUPN icon

Disciplined Investments’s Supernus Pharmaceuticals SUPN Stock Holding History

Disciplined Investments’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-3
Closed -$90 – 1361
2023
Q2 		$90 Buy
3
+2
+200% +$70 ﹤0.01% 1609
2023
Q1 		$36 Sell
1
-1
-50% -$38 ﹤0.01% 1649
2022
Q4 		$71 Buy
+2
New +$70 ﹤0.01% 1563

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Disciplined Investments's SUPN Position: Q3 2023 in Review

Disciplined Investments sold out of Supernus Pharmaceuticals (SUPN) in Q3 2023, closing a stake of 3 shares — an estimated $90 sold.

Disciplined Investments first reported a position in SUPN in Q4 2022 and held it in 3 quarters. The position peaked at $90 in Q2 2023. 238 funds tracked by Wall St. Rank hold SUPN as of Q3 2023.

  • Disciplined Investments reported no remaining Supernus Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Disciplined Investments sold 3 Supernus Pharmaceuticals shares in Q3 2023, an estimated $90.
  • Disciplined Investments first reported a position in Supernus Pharmaceuticals in Q4 2022 and held it in 3 quarters.
  • Disciplined Investments's Supernus Pharmaceuticals position peaked at $90 in Q2 2023.
  • 238 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2023.

Based on Disciplined Investments's 13F filing for Q3 2023, filed 14 Nov 2023.